Piper Jaffray Companies reiterated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research note released on Thursday, Marketbeat Ratings reports. They currently have a $67.00 price target on the biopharmaceutical company’s stock.
Several other brokerages also recently weighed in on RARE. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a sell rating to a hold rating in a report on Wednesday, January 24th. BidaskClub upgraded Ultragenyx Pharmaceutical from a sell rating to a hold rating in a report on Wednesday, January 24th. Jefferies Group upgraded Ultragenyx Pharmaceutical from a hold rating to a buy rating and boosted their price target for the company from $58.00 to $72.00 in a report on Monday, December 4th. Barclays boosted their price target on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an equal weight rating in a report on Tuesday, December 5th. Finally, Raymond James Financial reiterated a buy rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $68.76.
Ultragenyx Pharmaceutical stock opened at $50.00 on Thursday. Ultragenyx Pharmaceutical has a twelve month low of $41.67 and a twelve month high of $72.38.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 1,246.9% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,273 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 3,030 shares during the period. SG Americas Securities LLC purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth $156,000. Xact Kapitalforvaltning AB purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth $205,000. B. Riley Financial Inc. purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth $213,000. Finally, Aperio Group LLC purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth $254,000. 87.19% of the stock is owned by institutional investors.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.